Pharmacokinetics of 1,25-dihydroxyvitamin D3 glycosides from Solanum glaucophyllum extract given in a rumen bolus on blood mineral profiles in dry pregnant dairy cows. by Meyer-Binzegger, M et al.
Research in Veterinary Science 142 (2022) 70–77
Available online 19 November 2021
0034-5288/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Pharmacokinetics of 1,25-dihydroxyvitamin D3 glycosides from Solanum 
glaucophyllum extract given in a rumen bolus on blood mineral profiles in 
dry pregnant dairy cows 
M. Meyer-Binzegger a,b, C. Ollagnier a, L. Eggerschwiler a, K. Bühler c, P. Schlegel a,*, M. Meylan b 
a Agroscope, Ruminant Research Unit, 1725 Posieux, Switzerland 
b Clinic for Ruminants, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland 
c Herbonis Animal Health GmbH, 4302 Augst, Switzerland   








A B S T R A C T   
Providing tablets of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active metabolite of vitamin D3, 
in a rumen bolus may be used as prevention for periparturient hypocalcemia in dairy cows. This study inves-
tigated the pharmacokinetics of 1,25(OH)2D3 glycosides extracted from Solanum glaucophyllum (SGE) on blood 
serum 1,25(OH)2D3, Ca, P and Mg response in dry pregnant dairy cows. Boluses contained tablets of SGE which 
differed in their release properties (rapid release, slow release and combination) and galenics (200 μg uncoated, 
300 μg and 500 μg uncoated or coated, 2 × 500 μg uncoated). Nineteen blood samples were collected from 29 
cows between 96 h before and 336 h after bolus administration. Blood serum 1,25(OH)2D3, Ca and P increased 
between 12 h and 120 h, 12 h and 264 h and 24 h and 264 h, respectively. Highest values were reached at 30 h, 
72 h and 120 h for 1,25(OH)2D3, Ca and P, respectively. Baseline values were then reached at 216 h for 1,25 
(OH)2D3 and 336 h for Ca and P. Concentration of Mg decreased between 24 h and 216 h, before reaching values 
comparable to baseline at 264 h. Highest Ca values were obtained with the combined rapid and slow release 
properties (500 μg) and there was no effect from coating on pharmacokinetics. In conclusion, the antepartum 
oral SGE bolus administration may be suitable for the prevention of periparturient hypocalcemia.   
1. Introduction 
The sudden onset of milk production at calving time induces a drastic 
increase in calcium (Ca) requirements for dairy cows. In order to 
maintain a constant blood Ca level, the cow’s homeostatic regulation 
mechanisms increase Ca resorption from body reserves in the bones and 
intestinal Ca absorption. Blood Ca levels are regulated by parathyroid 
hormone (PTH), calcitonin and 1,25-dihydroxyvitamin D3 (1,25 
(OH)2D3), the biologically active metabolite of vitamin D3. The physi-
ological range of blood serum Ca concentration is between 2.0 and 2.8 
mmol/l; the range between 1.4 and 2.0 mmol/l is considered to corre-
spond to subclinical hypocalcemia; levels <1.4 mmol/l are associated 
with clinical hypocalcemia, i.e. with a high risk for milk fever occur-
rence (Braun et al., 2009; DeGaris and Lean, 2009). Reported incidence 
of puerperal clinical hypocalcemia in dairy cows varies between 1% and 
10% (Martin-Tereso and Martens, 2014; DeGaris and Lean, 2009). These 
values depend on parity as primiparous cows are less susceptible than 
multiparous cows, especially from the 3rd lactation onwards (Caixeta 
et al., 2015; Goff, 2014; Oetzel, 2011; Reinhardt et al., 2011). An inci-
dence of subclinical hypocalcemia of 50% or more has been reported for 
older cows (Caixeta et al., 2015; Reinhardt et al., 2011; Venjakob et al., 
2017). Low postpartum blood Ca levels can predispose to various pu-
erperal diseases such as dystocia, uterus prolapse, placental retention, 
metritis, mastitis, abomasum displacement and ketosis (Mulligan et al., 
2006; Rodriguez et al., 2017; Seifi and Kia, 2018). Strategies to limit the 
risk of milk fever occurrence include: a diet low in Ca (Thilsing-Hansen 
et al., 2002; Roche et al., 2018; Kerwin et al., 2019); presenting a 
negative dietary cation-anion balance during the last three to four weeks 
prepartum (Goff, 2014; Martin-Tereso and Martens, 2014; Lean et al., 
2019; Santos et al., 2019); oral (Hove and Kristiansen, 1984) or paren-
teral administration of vitamin D3 (injections) a few days before (Goff, 
2014; Ishii et al., 2015; Starič and Hodnik, 2021) or immediately after 
calving (Vieira-Neto et al., 2017; Vieira-Neto et al., 2021); as well as 
parenteral (Wilms et al., 2019; Amanlou et al., 2016; Miltenburg et al., 
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2016) or oral administration of soluble forms of Ca around parturition 
(Goff, 2008; Thilsing-Hansen et al., 2002) are recommended as well, in 
the case the two main dietary strategies would be insufficient. 
In a natural environment with sufficient ultraviolet B light, rumi-
nants can fulfill most of their vitamin D3 requirements through synthesis 
in addition to vitamin D3 ingestion over feed sources (Hymøller and 
Jensen, 2010). The de-novo synthesis of vitamin D3 involves splitting of 
the cholesterol steroid ring by ultraviolet B light in the skin. Vitamin D3 
is first hydroxylated in the liver to 25-hydroxyvitamin D3 (25(OH)D3). A 
second hydroxylation triggered among others by PTH, which is secreted 
by the parathyroid gland in response to low blood Ca concentration, 
results in the synthesis of the active metabolite 1,25(OH)2D3 in the 
kidneys (DeGaris and Lean, 2009; Goff, 2014). Active intestinal Ca up-
take to the blood compartment, aside from passive absorption through 
paracellular transport, is promoted by increased expression of Ca 
channels in the apical membrane of intestinal epithelial cells, of cal-
bindins (Ca binding proteins for intracellular Ca transport), and of 
extrusion systems (for Ca release from the basolateral membrane) under 
the influence of 1,25(OH)2D3 (Goff, 2014; Martin-Tereso and Martens, 
2014; van de Graaf et al., 2006). 
Therefore, oral administration of the biologically active metabolite 
1,25(OH)2D3 may be an efficient strategy to prevent hypocalcemia in 
periparturient cows. The plant Solanum glaucophyllum contains 1,25 
(OH)2D3 in the form of glycosides. The glycosides are cleaved by rumen 
bacteria and free 1,25(OH)2D3 is released after ingestion (Napoli et al., 
1977; Horst et al., 2003). Feeding dried leaves of S. glaucophyllum to 
cows starting two weeks before parturition permitted to maintain 
slightly higher blood serum Ca levels at and in the first days after calving 
(Horst et al., 2003; Ishii et al., 2015). However, correct timing and slow 
withdrawal of the exogenous source of 1,25(OH)2D3 are crucial when 
using external sources of 1,25(OH)2D3. Due to the potential of a reduced 
endogenous 1,25(OH)2D3 production in these cases, sudden withdrawal 
can lead to a rebound effect which can trigger late milk fever (Horst 
et al., 2003; Goff, 2008). 
Concentrated 1,25(OH)2D3 glycosides can be extracted from 
S. glaucophyllum, allowing for the development of products which should 
be easier to manage than leaves and easier to apply to cows for the 
prevention of hypocalcemia and milk fever. Tablets of 1,25(OH)2D3 
glycosides extracted from S. glaucophyllum (SGE) were developed to 
enable a combination of rapid and long-acting slow release of 1,25 
(OH)2D3 in the rumen to provide a suitable window of application with 
an optimal release pattern for the prevention of hypocalcemia in dairy 
cows. These SGE tablets can then be incorporated in a single ruminal 
bolus to be applied prior to calving. 
The aim of this study was to investigate the pharmacokinetics of 1,25 
(OH)2D3 and the response in Ca, P and Mg blood concentrations in dry 
pregnant dairy cows following the administration of oral boluses con-
taining SGE tablets differing in their release properties (rapid, slow) and 
galenics (uncoated, coated). This, to determine the influence of the 
release properties and the galenic form on the pharmacokinetics and 
responses and the optimal administration time prior to calving of the 
bolus combining SGE tablets with the two release properties. 
2. Materials and methods 
2.1. Animals and housing 
Twenty-nine healthy, dry pregnant Holstein and Red Holstein dairy 
cows (220 to 257 d after successful insemination) from the Agroscope 
dairy herd (Posieux, Switzerland) were allocated to five successive 
groups according to parity (primiparous, multiparous) and expected 
calving date. One group consisted of six primiparous cows, and four 
groups of multiparous cows (2nd to 6th parity, three groups with six cows 
and one group with five cows). Each cow within a group was randomly 
allocated to one of six treatments, whereby during the last two multip-
arous groups, cows were allocated in order that parity numbers were 
evenly distributed between treatments. 
The cows were housed in a tie-stall barn with rubber mat flooring 
during the entire experimental period, which lasted for 14 d per animal. 
The cows were adapted to the diet for 10 to 13 d prior start of the 
experiment and a veterinarian performed a complete physical exami-
nation of each cow. Each cow was weighted 4 days prior start and at the 
end of the experiment. After completion of the experiment, the cows 
were housed in individual boxes with deep straw until calving. The 
course of parturition was recorded and the cows were returned to the 
free stall barn a few days after calving. All procedures were conducted in 
accordance with the Ordinance on Animal Protection and the Ordinance 
on Animal Experimentation. The experiment was approved by the 
competent authorities (Authorization 2017_24_FR). 
2.2. Diet 
The cows had free access to water and hay (2nd seasonal harvest; 
growth development stage “begin heading” according to Dactylis glom-
erata; mixed botanical composition with 78% graminea, 19% legumes, 
3% other plants) and were fed daily 300 g of pelleted mineralized 
concentrate. This concentrate was formulated to meet or exceed the 
Swiss feeding recommendations for dry and pregnant cow (Agroscope, 
2017) and consisted of wheat bran, apple pomace, oats, sodium chlo-
ride, magnesium oxide, molasses, trace minerals and vitamin premix. 
The trace mineral and vitamin premix contained 676′000 IU vitamin D3 
per kg and was included in the mineralized concentrate at 1.6%. Daily 
hay intake was calculated twice as the difference in weight between 
offered and refused amounts on three consecutive days (d3 to d5 and 
d10 to d12). Individual water consumption was recorded daily. 
2.3. Treatments 
The 1,25(OH)2D3 provided in form of glycosides was extracted from 
S. glaucophyllum leaves and compounded into galenic tablet formula-
tions (Herbonis Animal Health GmbH, Augst, Switzerland). The rapid 
release (RR) tablets were uncoated (u) and the slow release (SR) tablets 
were either coated (c) or not (u). The tablets were filled into gelatin- 
based capsules with dolomite and CaMg(CO3)2 as ballast to produce 
bolus formulations containing a total of 200, 300 and 500 μg 1,25 
(OH)2D3 from RR, SR and a combination of RR and SR tablets, respec-
tively. The bolus with 500 μg 1,25(OH)2D3 equals the sum of the SR and 
RR tablets from boluses containing 200 and 300 μg 1,25(OH)2D3, 
respectively. The bolus with 500 μg 1,25(OH)2D3 was studied previously 
(Bachmann et al., 2017), but with different release properties and 
galenics. 
The six treatments consisted of the oral administration of one 200u 
(RR only), 300u (SR only, uncoated), 500u (combination of RR and SR, 
uncoated), 300c (SR only, coated) and 500c (combination of RR and SR, 
coated) bolus and the simultaneous oral administration of two 500u 
boluses (total 1000 μg 1,25(OH)2D3, 2x500u). 
The bolus was applied on d0 to each cow per group using a bolus 
applicator (V-Grip™ Bolus Gun, item 64,314, MAI Animal Health, 
Melksham, Wiltshire UK). The treatment 2x500u was applied to five 
cows (vs. six for the other treatments), as one animal assigned to this 
treatment dropped out prior to the start of the study and could not be 
replaced, because no suitable dry and pregnant cow (220–257 days after 
successful insemination) was available at that time. 
2.4. Sample collection and preparation 
Nineteen blood samples were taken from each cow at -96 h, -72 h, 0 
h, 1 h, 3 h, 6 h, 12 h, 18 h, 24 h, 27 h, 30 h, 48 h, 72 h, 96 h around bolus 
application, as well as at 120 h (d5), 168 h (d7), 216 h (d9), 264 h (d11) 
and 336 h (d14) after treatment. Sample of 0 h was taken on d0 at 08 h 
00 immediately prior to bolus application. Within a group and sampling 
time, blood was collected within 30 min, always in the same order of 
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cows. Blood was sampled from the jugular vein, alternatively on the 
right and left side, using disposable cannulae (Vacuette 20G, Greiner Bio 
One International GmbH, Solingen, Germany) and serum vacutainers 
without anticoagulant (S-Monovette, Sarstedt AG + Co. KG, Nümbrecht, 
Germany). Serum vacutainers were centrifuged within 2 h of sampling at 
1500 x g for 15 min followed by 4000 x g for 2 min. The serum was 
immediately separated and stored at − 20 ◦C until analyses were per-
formed. Hay and concentrate samples were collected twice a week and 
pooled over two-week periods. Pooled hay and pooled concentrate 
samples were milled separately (1.0 mm, Brabender mill, Duisburg, 
Germany) and preserved in glass bottles until analysis. One bolus of each 
formulation was randomly selected and the tablets were milled after 
extraction from the gelatin capsules and preserved in glass bottles until 
analysis. 
2.5. Chemical analyses 
Blood serum concentration (0 h, 12 h, 30 h, 48 h, 72 h, 120 h and 
216 h) and SGE Bolus content of 1,25(OH)2D3 were determined using 
ELISA kits (Kit 2112, Immundiagnostik, Bensheim, Germany). Concen-
trations of blood serum Ca, P and Mg (− 96 h to 336 h) were determined 
in duplicates colorimetrically, for Ca with an autoanalyzer Cobas Mira 
(Roche, Basel, Switzerland), and for P and Mg using commercial kits 
with an autoanalyzer Alizé 200 (BioMérieux, Marcy l’Etoile, France). 
Dry matter (DM), ash, crude fiber (CF), crude protein (CP) and mineral 
contents (Ca, P, Mg, K and Na), respectively in hay and mineralized 
concentrate, were determined as described by Oberson et al. (2019). 
2.6. Statistical analyses 
The individual cow was considered as the subject unit of the exper-
iment and acted as its own control, based on initial baseline values. 
Initial baseline values for repeated blood analyses were calculated as a 
mean of values from − 96 h, − 72 h and 0 h. No control group needed to 
be added to the defined six groups, as blood serum Ca concentrations 
remain constant during the weeks prior to calving (Kimura et al., 2006; 
Rérat and Schlegel, 2014; Starič and Hodnik, 2021). Peak observed drug 
concentration (Cmax), time of peak concentration (Tmax), area under the 
concentration-time curve (AUC) and residence time for serum 1,25 
(OH)2D3, Ca, P and Mg were calculated for each cow by non-
compartmental analysis of the orally administered 1,25(OH)2D3. This 
was done using R software (version 3.5.3, with NonCompart, ncar, dplyr 
and nlme packages) including the selected conditions of extravascular 
route, trapezoidal rule for measurement of AUC with linear-up linear- 
down for calculation and best fit for the terminal slope determination. 
Non-repeated animal performance data (hay and water intake and 
body weight) as well as Cmax, Tmax, AUC and residence time of blood 
serum values were analyzed using the general linear model of SYSTAT 
13 (SYSTAT Software Inc.) following the model Yij = μ + Groupi +
Treatmentj + εij where Yij is the response, μ the least-squares mean, groupi 
the fixed effect of the group (i = 1–5), treatmentj the fixed effect of the 
experimental treatment (j = 200u, 300u, 300c, 500u, 500c and 2x500u), 
and εij the random error. Repeated blood serum concentrations were 
analyzed using the mixed model of SYSTAT 13 (SYSTAT Software Inc.) 
following the model Yijklm = μ + Groupi + Treatmentj + Timek + Inter-
actionl + Cowm + εijklm where Yijklm is the response, μ the least-squares 
mean, groupi the fixed random effect of the group, treatmenti the fixed 
effect of the experimental treatment, timek the fixed effect of blood 
sampling time (k = 0 h, 1 h, 3 h, 6 h, 12 h, 18 h, 24 h, 27 h, 30 h, 48 h, 72 
h, 96 h, 120 h, 168 h, 216 h, 264 h and 336 h), interactionl the interaction 
of treatmenti and timek, Cowm the fixed random effect of the cow and 
εijklm the random error. Differences between least square means were 
considered as significant at P ≤ 0.05 and tendencies were noted at P <
0.10. Comparisons among least square means and between application 
of uncoated and coated tablets (300u and 500u vs. 300c and 500c) were 
calculated using Tukey’s contrasts. 
3. Results 
3.1. Animals, diet and feed intake 
The analyzed boluses had a 1,25(OH)2D3 content of 198, 272, 491, 
292 and 517 μg, for 200u, 300u, 500u, 300c and 500c, respectively. All 
cows tolerated oral bolus application well and remained healthy during 
the experiment and the observational post experimental period which 
ended two days after calving. No adverse effects were observed. 
The 1,25(OH)2D3 content in each bolus formulation was consistent 
with the formulated values. The nutrient concentration (mean ± SD) in 
the consumed hay (n = 4) was, per kg DM, 4.9 MJ net energy for 
lactation, 287 ± 6 g CF, 149 ± 4 g CP, 99 ± 18 g ash, 6.2 ± 0.4 g Ca, 4.4 
± 0.1 g P, 1.8 ± 0.1 g Mg, 39 ± 0.7 g K and 0.6 ± 0.1 g Na. The nutrient 
concentration in the consumed mineralized concentrate (n = 4) was, per 
kg DM, 118 ± 1 g CF, 119 ± 3 g CP, 181 ± 1 g ash, 7.8 ± 0.8 g Ca, 6.0 ±
0.2 g P, 22.0 ± 0.6 g Mg, 8.5 ± 0.3 g K and 38.5 ± 2.3 g Na. Hay intake 
(12.5 ± 0.7 kg DM/d, least square mean ± SEM), water intake (78.9 ±
6.4 l/d) and body weight (737 ± 31 kg at d-4; 747 ± 33 kg at d14) did 
not differ (P > 0.10) among treatments. 
The cows calved 25 ± 6 d after the last blood sampling, with a parity 
of 3.0 ± 0.7 without differences (P > 0.10) among treatments. The 29 
calves (12 females and 17 males) were healthy. 
3.2. Pharmacokinetics of 1,25(OH)2D3 after oral bolus application 
Following oral bolus application, 1,25(OH)2D3 blood serum con-
centration (Fig. 1; Supplementary Table 1) increased (P < 0.001), 
compared to baseline (30 pmol/l), within the timeframe of 12 h (149 
pmol/l) to 120 h (92 pmol/l) with maximal values observed from 30 h 
(207 pmol/l) to 48 h (187 pmol/l). Blood serum 1,25(OH)2D3 returned 
to baseline at 216 h, therefore analyses for 1,25(OH)2D3 was dis-
continued after that sampling time. The mean increase in blood serum 
1,25(OH)2D3 from the baseline was 513% between 12 h and 120 h after 
bolus application. The time dependent response was more pronounced 
in 300u, 500u, 500c and 2x500u than in 200u and 300c (time x treat-
ment interaction, P < 0.05). Overall, blood serum 1,25(OH)2D3 tended 
(P = 0.08) to be higher in 500u and 500c than 200u and contrast 
analysis revealed that blood serum 1,25(OH)2D3 did not differ (P >
0.10) between uncoated and coated formulations. No differences (P >
0.10) among treatments were observed for Tmax and residence time of 
serum 1,25(OH)2D3, but Cmax of 500u was twice as high compared to 
200u (P = 0.09) and AUC of 500u and 500c were twice as high compared 
to 200u (P = 0.08; Table 1). 
3.3. Changes in Ca, P and Mg blood levels 
Following SGE bolus application, blood serum Ca concentration 
(Fig. 2; Supplementary Table 2) increased (P < 0.001) from the baseline 
(2.23 mmol/l) within the timeframe of 12 h (2.36 mmol/l) to 264 h 
(2.49 mmol/l), with maximal values observed from 48 h (2.72 mmol/l) 
to 96 h (2.69 mmol/l), before returning to values comparable (P > 0.10) 
to the baseline at 336 h (2.25 mmol/l). The mean increase in blood 
serum Ca from the baseline was 16% between 12 h and 264 h after bolus 
application. Between 0 h and 336 h, the blood serum Ca of 300c was 4% 
lower (P < 0.001) than of 500c and 2x500u. There was no interaction of 
time x treatment (P > 0.10). Contrast analysis revealed that blood serum 
Ca response did not differ (P > 0.10) between uncoated and coated 
formulations. No differences among treatments were observed for Tmax 
and residence time of blood serum Ca, but Cmax was higher (P < 0.05) 
with 2x500u compared to 300c, and AUC was higher (P < 0.05) with 
2x500u compared to 200u and 300c (Table 1). 
Similarly, blood serum P concentration (Fig. 3; Supplementary 
Table 3) increased after SGE bolus application (P < 0.001) from the 
baseline (1.50 mmol/l) within the timeframe of 24 h (1.94 mmol/l) to 
264 h (2.00 mmol/l), with maximal values observed from 72 h (2.55 
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mmol/l) to 120 h (2.73 mmol/l), before returning to values comparable 
(P > 0.10) to the baseline at 336 h (1.54 mmol/l). The mean increase in 
blood serum P from the baseline was 55% between 24 h and 264 h after 
bolus application. The response of blood serum P was similar between 
treatments (P > 0.10) and there was no time x treatment interaction (P 
> 0.10). Contrast analysis revealed that blood serum P response did not 
differ (P > 0.10) between uncoated and coated formulations. No dif-
ferences among treatments were observed for Cmax, Tmax, AUC and 
residence time of serum P (Table 1). 
Blood serum Mg concentration (Fig. 4; Supplementary Table 4) 
decreased (P < 0.001) from the baseline (0.91 mmol/l) within the 
timeframe of 24 h (0.83 mmol/l) to 216 h (0.82 mmol/l) with minimal 
values observed from 48 h (0.76 mmol/l) to 96 h (0.79 mmol/l), before 
reaching values comparable (P > 0.10) to the baseline at 264 h (0.86 
mmol/l). The mean decrease in blood serum Mg from the baseline was 
10% between 24 h and 216 h after bolus application. The response of 
blood serum Mg was similar between treatments (P > 0.10) and there 
was no time x treatment interaction (P > 0.10). Contrast analysis 
revealed that blood serum Mg response did not differ (P > 0.10) between 
uncoated and coated boluses. The highly variable blood serum Mg 
prevented to calculate accurate individual AUC and therefore the mean 
residence time. 
4. Discussion 
The oral application of boluses containing 1,25(OH)2D3 glycosides 
Fig. 2. Pharmacokinetics of calcium in blood serum (least square means ± SE) over time after single oral bolus administration (time effect: P < 0.001; treatment 
effect: P < 0.001; time x treatment interaction: P > 0.10). 
Fig. 1. Pharmacokinetics of 1,25(OH)2D3 in blood serum (least square means ± SE) over time after single oral bolus administration (time effect: P < 0.001; treatment 
effect: P < 0.001; time x treatment interaction: P > 0.10). 
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from S. glaucophyllum induced an increased blood serum 1,25(OH)2D3 
concentration. Subsequently, increased serum Ca and P concentrations 
and decreased serum Mg concentrations were observed in all treatments. 
This confirms the pharmacodynamical effect of SGE after oral admin-
istration as a bolus in pregnant dry cows on blood serum Ca, P and Mg 
concentrations. These results are in accordance with previous reports by 
others who fed the leaves of this plant (Roux et al., 1979; Horst et al., 
2003; Ishii et al., 2015) or their extracted 1,25(OH)2D3 glycosides 
(Bachmann et al., 2017). 
Blood serum 1,25(OH)2D3 concentrations between 12 and 48 pmol/ 
ml have been reported in non-pregnant non-lactating cows, that rise to 
48–120 pmol/ml in late pregnancy and to 240 pmol/ml around the time 
of parturition and onset of lactation. Elevated values up to >720 pmol/ 
ml can be observed during severe hypocalcemia (Reinhardt et al., 1988). 
In the present study, the values observed prior to bolus administration in 
cows with advanced pregnancy, but not yet close to parturition were 
within these ranges and raised significantly from 12 h following bolus 
administration. However, the observed serum 1,25(OH)2D3 concentra-
tions did not exceed those reported in cows at the time of calving or in 
response to hypocalcemia after any treatment. 
The mean serum Ca values prior to bolus application were within the 
normal range of 2.0–2.8 mmol/l. As Ca levels several weeks prior to 
parturition (220 to 257 days after successful insemination) can be 
assumed to be stable, the observed increase in Ca serum concentrations 
after bolus application solely originated from the orally applied product. 
The effect of preventive measures against hypocalcemia is meant to 
occur within 48 h after calving in order to limit the risk of milk fever 
(Goff, 2008; Venjakob et al., 2017). The maximal observed serum Ca 
Fig. 3. Pharmacokinetics of phosphorus in blood serum (least square means ± SE) over time after single oral bolus administration (time effect: P < 0.01; treatment 
effect: P < 0.001; time x treatment interaction: P > 0.10). 
Fig. 4. Pharmacokinetics of magnesium in blood serum (least square means ± SE) over time after single oral bolus administration (time effect: P < 0.001; treatment 
effect: P < 0.001; time x treatment interaction: P > 0.10). 
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concentrations exceeded the normal range with 500c and 2x500u, only 
slightly and for a limited duration of 1–2 days. Therefore, adverse effects 
such as calcinosis should not be expected after single oral administration 
of one or two SGE boluses in the galenic forms used in the present study. 
Especially not during times of challenged Ca-metabolism as it is to be 
expected around calving. The observed plateau followed by a slow 
decrease in serum Ca concentrations lasted for 10 days. This long time- 
lapse should prevent delayed hypocalcemia observed in periparturient 
cows after abrupt withdrawal of feeding S. glaucophyllum leaves (Horst 
et al., 2003) and enlarges the window for the prevention of milk fever 
with a single application bolus. 
The mean serum P values prior to bolus application were within the 
normal range of 1.4–2.6 mmol/l (Constable et al., 2017). The observed 
increase in P serum concentration after bolus application started later, 
but was more pronounced than that of Ca. Others (Bachmann et al., 
2017; Ishii et al., 2015) have reported an increase in serum P concen-
trations after administration of 1,25(OH)2D3 to cows outside the peri-
parturient period, i.e. prior to the activation of Ca-mobilizing 
mechanisms such as increased PTH secretion, but these authors did not 
offer an explanation for this observation. Increased intestinal P ab-
sorption after supply of 1,25(OH)2D3 has been reported in rodents 
(Marks et al., 2006) and in pigs (Fox and Care, 1979), but the mechanism 
(s) by which serum P concentrations increase in cows after treatment 
with 1,25(OH)2D3 (and independently of PTH) remain unclear (Ishii 
et al., 2015). A positive association between serum Ca and P values has 
also been reported in parturient cows with and without clinically rele-
vant hypocalcemia (Venjakob et al., 2017; Megahed et al., 2018). The 
observed decrease in serum P concentrations in those cows was attrib-
uted to increased P losses over colostrum and milk, as well as to 
increased renal P excretion under the influence of PTH secreted in 
response to hypocalcemia. The delayed serum P concentration increase 
compared to Ca observed here has also been reported by others (Bach-
mann et al., 2017; Ishii et al., 2015). A 12 h delay between the onset of 
increased Ca and P absorption was observed in isolated pig intestine 
perfused with a 1,25(OH)2D3 solution, but not after perfusion with 
S. glaucophyllum extracts (Fox and Care, 1979). The reasons for these 
discrepancies and their mechanisms remain unknown. 
The mean serum Mg values prior to bolus application were mostly 
within the normal range of 0.8–1.2 mmol/l (Martens, 2016). The 
observed decrease in serum Mg concentrations after treatment with 1,25 
(OH)2D3 is in accordance with previous reports (Ishii et al., 2015; Lit-
tledike and Horst, 1982). This finding does not confirm the findings of 
Bachmann et al. (2017) who did not observe any effect of SGE on serum 
Mg concentrations. Magnesium is known to play an important role in the 
periparturient period as hypomagnesemia reduces PTH secretion as well 
as the tissue (bone, kidneys) response to PTH, and thus can precipitate 
the occurrence of milk fever (Goff, 2008, 2014; DeGaris and Lean, 
2009). In contrast to the hormonal regulation of Ca and P via PTH and 
1,25(OH)2D3, Mg homeostasis is primarily regulated by dietary Mg 
intake and gastrointestinal absorption on one hand, and renal excretion 
on the other hand. However, increased renal reabsorption of Mg under 
the influence of PTH through modification of the renal threshold for Mg 
excretion has been suggested (Martin-Tereso and Martens, 2014; Mar-
tens, 2016). The decrease in serum Mg concentrations observed in the 
present study in dry pregnant cows outside the periparturient period 
may be a consequence of decreased PTH levels (and thus increased renal 
excretion of Mg) caused by the increase in serum Ca values after treat-
ment with 1,25(OH)2D3 glycosides from S. glaucophyllum. This could not 
be confirmed in the frame of the present study, as urinary Ca, P and Mg 
were not measured. This slight effect on serum Mg concentrations 
should not be of clinical relevance under the metabolic conditions of 
cows in the periparturient period (except in case of insufficient dietary 
Mg intake). 
It has been known for decades that feeding leaves of S. glaucophyllum 
leads to an increase in serum Ca and P concentrations which can be used 
for the prevention of parturient hypocalcemia (Roux et al., 1979). Both 
dose and timing of treatment with 1,25(OH)2D3 glycosides from 
S. glaucophyllum have been reported to be important for the prevention 
of hypocalcemia (Ishii et al., 2015; Bachmann et al., 2017). Although the 
effects of S. glaucophyllum on serum Ca concentrations have already been 
investigated by these authors, the aim of the present study was to 
describe the pharmacokinetics and the effects on blood serum 1,25 
(OH)2D3, Ca, P and Mg concentrations of new formulations in a new 
application form. The new formulations achieved through combination 
of three types of 1,25(OH)2D3 releasing tablets (rapid or slow release, 
coated or uncoated) were conditioned in a single oral bolus that should 
be easy to use in practice for the prevention of milk fever. 
The present results confirm that a single oral SGE bolus adminis-
tration leads to a rapid increase in serum 1,25(OH)2D3 concentrations 
with maxima observed after 1.5 to 2 days and a return to pre-treatment 
values within 9 days. It also leads to a rapid increase in serum Ca con-
centrations (within 12 h) with maxima observed between 2 and 4 days 
and a progressive return to pre-treatment values within 11 days, which 
offers a relatively long window for treatment prior to calving. Timely 
ante partum application is the greatest challenge associated with 1,25 
(OH)2D3 treatment to prevent milk fever (Goff and Horst, 1990; Goff, 
2014; Perruchoud et al., 2017), thus a reasonably extended window of 
opportunity for treatment reduces the risk of too early or too late 
application of 1,25(OH)2D3. The coated and uncoated properties of the 
SGE tablets resulted to similar blood serum Ca, P and Mg patterns and 
Table 1 
Blood serum pharmacokinetics of 1,25(OH)2D3, calcium and phosphorus.    
Treatment  
Parameter, unit 200u 300u 300c 500u 500c 2x500u SEM P-value 
1,25(OH)2D3 
Cmax, pmol/l 137 265 148 295 279 238 45.9 0.09 
Tmax, h 19 42 44 37 37 36 7.4 n.s. 
AUC, pmol/l x min 14,309 25,611 17,547 28,643 28,659 25,202 1,622 0.08 
Residence time, h 72 79 85 76 73 83 3.6 n.s. 
Ca 
Cmax, mmol/l 2.79ab 2.79ab 2.77b 2.79ab 2.89ab 2.94a 0.035 <0.05 
Tmax, h 96 149 139 110 82 61 24.9 n.s. 
AUC, mmol/l x min 842b 856ab 844b 853ab 876ab 884a 9.0 <0.05 
Residence time, h 165 165 165 165 164 164 0.9 n.s. 
P 
Cmax, mmol/l 3.03 2.81 2.89 3.01 2.75 2.83 0.123 n.s. 
Tmax, h 134 120 139 139 115 71 24.6 n.s. 
AUC, mmol/l x min 727 757 760 799 722 756 44.5 n.s. 
Residence time, h 155 162 162 163 160 162 2.9 n.s. 
Bolus with either uncoated (u) or coated (c) tablets totaling 200, 300 and 500 μg 1,25(OH)2D3 provided as 1,25(OH)2D3-glycosides from Solanum glaucophyllum. 
a,b: values with different small letter superscripts differed significantly (P ≤ 0.05) n.s.: non significant. 
Cmax: peak concentration of least square means. 
Tmax: time of peak concentration of least square means. 
AUC: area under the concentration-time curve. 
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this likely reflects that the slow release tablet formulation already 
reached the maximal release time without requiring any coating. The 
difference up to a factor five (200 vs. 1000 μg) in the administered 1,25 
(OH)2D3 doses was not reflected in Ca, P and Mg serum variations of 
corresponding magnitude. While the rapid release tablets (200u) in most 
cases produced the most limited effects, the double application of the 
combined rapid and slow release tablets (2x500u) were not always 
associated with the highest response. An imperfect dose-response rela-
tionship after S. glaucophyllum application was also observed by Ishii 
et al. (2015) and Bachmann et al. (2017), although their experimental 
designs do not allow direct comparisons except for one experiment, 
where non-pregnant non-lactating cows were fed 0, 0.5, 1.0 and 2.0 mg/ 
kg body weight of 1,25(OH)2D3 from dried S. glaucophyllum leaves 
during 14 days. This resulted in increases of serum Ca and P concen-
trations parallel to the dosage of 1,25(OH)2D3 (Ishii et al., 2015). In the 
present study, the agreement between rapid, slow and their combina-
tion, resulting to a certain dose-response was better for Ca than for P, 
and the highest serum Ca values were obtained with the 2x500u, in 
terms of Cmax as well as of AUC. Treatment with two SGE boluses con-
taining 500 μg of 1,25(OH)2D3 each was not included as a therapeutic 
option, but to monitor the effects of erroneous (double) application. This 
treatment produced the highest elevation of serum Ca (not P) but did not 
lead to prolonged elevation of serum Ca above the normal range. In 
general, in no treatment were any adverse effects observed during the 
experiment or while the consecutive post-experimental observation 
period. These results suggest that the application of two instead of one 
bolus should not lead to toxicity in case of a dosing error in the field, 
especially as this treatment would be applied only once yearly around 
the time of parturition. Finally, the slow decrease in serum Ca concen-
tration after the plateau phase should prevent delayed hypocalcemia 
(rebound effect) such as observed a week after withdrawal of 
S. glaucophyllum leaves fed from 6 days before until 14 days after 
parturition (Horst et al., 2003). 
Finally, the application of uncoated 500 μg SGE bolus appears to be 
adequate for further investigations in pregnant cows around the time of 
parturition as a mean to reduce the risk of hypocalcemia occurrence. 
This, because the highest blood serum Ca levels were obtained with this 
bolus and because there were no differences between the coated and 
uncoated boluses. Indeed, the blood serum Ca concentration has 
recently been shown to be maintained within the normal range over the 
critical first two days of lactation in multiparous cows after the appli-
cation of one 500 μg SGE bolus three to four days prior to expected 
calving (Meyer-Binzegger et al., 2021). 
5. Conclusion 
The bolus containing 1,25-dihydroxyvitamin D3 glycoside extracts of 
S. glaucophyllum was successful in modifying blood serum 1,25(OH)2D3, 
Ca, P and Mg concentrations in dry pregnant dairy cows over several 
days. The antepartum oral SGE bolus (independent of release properties) 
administration may be suitable for the prevention of periparturient 
hypocalcemia. The simultaneous application of two boluses with 500 μg 
1,25(OH)2D3, that may potentially happen erroneously in practice, did 
not show any adverse effect compared to one single bolus regarding 
dairy (Amanlou et al., 2016) cow health or the measured blood 
parameters. 
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